Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
In the context of the University of Rochester's Phase 2 clinical trial for breast abscesses, a lipid emulsion (specifically Nutrilipid or Intralipid) is utilized as a physical adjunct in methylene blue photodynamic therapy (MB-PDT). Following the drainage of the abscess and the administration of methylene blue, the lipid emulsion is infused into the cavity at a diluted concentration (0.1%). Its primary role is to serve as a light-scattering medium that homogenizes the distribution of 665 nm laser light delivered via an optical fiber. By ensuring a uniform light dose reaches the entire surface of the abscess cavity walls, the emulsion facilitates the effective activation of methylene blue to generate cytotoxic reactive oxygen species, thereby enhancing bacterial disinfection as an adjunct to standard percutaneous drainage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lipid emulsion.